|
|
||||||||



* Division of Pulmonary, Allergy, and Critical Care Medicine, and
Division of Cardiology, Duke University Medical Center, Durham, NC 27710
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Animal models of asthma are frequently used to explore mechanisms of allergic responses. In the most widely used mouse model of asthma, animals are first sensitized by an i.p. injection of OVA complexed with aluminum hydroxide (alum). OVA challenge of sensitized mice results in many of the responses seen in asthmatic individuals, including eosinophilic inflammation, production of Th2 cytokines, increases in serum IgE, and airway hyperreactivity. However, there is considerable variation in procedures that different laboratories use to challenge sensitized mice. In some studies, allergen exposures are restricted to a single day (10), or continue for 3 days, 5 days, 7 days, 10 days, and even as long 6 wk (11). Other differences include the route of challenge, which can be by intratracheal instillation, oropharyngeal application, or inhalation of OVA-based aerosol. In view of these procedural differences among various laboratories, it is perhaps not surprising that endotoxin has been reported to both increase (12, 13, 14, 15) and decrease (16, 17, 18, 19, 20, 21, 22) the intensity of allergic responses, and a comprehensive understanding of the mechanisms by which endotoxin affects allergic responses has remained elusive.
The goals of the present study were 2-fold. First, we sought to determine whether very low levels of endotoxin, closer to those found in ambient environments, would impact pulmonary allergic responses in an experimental setting. Second, we investigated whether the duration of allergen exposure affected the impact of endotoxin on allergic responses. Because low levels of endotoxin are present in commercially available OVA (16), we studied allergic responses to this protein in C57BL/6J mice and genetically matched mice lacking the TLR4 (tlr4), which is required for signaling responses to endotoxin (23). These studies revealed that wild-type and tlr4-deficient mice had similar responses to OVA containing low levels of endotoxin after short-term allergen exposures. However, tlr4-deficient mice had dramatically enhanced pulmonary allergic responses compared with C57BL/6 mice when challenged with OVA for prolonged periods. These findings demonstrate that in the presence of very low levels of endotoxin, tlr4-dependent signaling attenuates ongoing allergic responses in the lung.
| Materials and Methods |
|---|
|
|
|---|
The tlr4/ and tlr2/ mice were provided by Dr. S. Akira (Osaka University, Osaka, Japan) (24), and backcrossed for 810 generations onto a C57BL/6J background. Age- and gender-matched C57BL/6J mice were purchased from The Jackson Laboratory. Experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee at Duke University Medical Center, and were conducted in accordance with the standards established by the U.S. Animal Welfare Acts.
OVA sensitization and challenge
Mice were sensitized on days 0 and 7 by i.p. injections of 10 µg of OVA (Sigma-Aldrich) complexed with aluminum hydroxide (Pierce). Beginning on day 14, mice were exposed daily for 20 min to an aerosol of 1% OVA (Sigma-Aldrich) generated using an Ultra-Neb99 (DeVilbiss Healthcare). The number of daily allergen exposures ranged from 1 to 21. Animals were harvested 24 h after the last aerosol challenge.
Analysis of airway inflammation, airway hyperresponsiveness, and serum IgE
Whole lung lavage and cell differentials were determined, as previously described (25). A luminex instrument (Bio-Rad) was used to evaluate protein concentrations of IL-2, IL-5, and IFN-
(Bio-Rad). ELISA kit was used to evaluate IL-13 (R&D Systems) and IFN-
(PBL Biomedical). Serum IgE and IgG2a levels were detected by ELISA (BD Pharmingen). Unrestrained whole-body plethysmography (Buxco Electronics) was conducted, and measurements were obtained at baseline and after stimulation with inhaled methacholine (0, 5, 10, and 25 mg/ml), as previously described (25).
Analysis and removal of endotoxin from OVA
Levels of endotoxin in OVA were measured by the limulus amebocyte lysate assay (BioWhittaker), and were
70 EU/mg. In some experiments, endotoxin in the OVA was reduced with Detoxi-Gel (Pierce). In other experiments, the OVA was supplemented with additional endotoxin (Sigma-Aldrich), and generated aerosols with this mixture. Aerosol was sampled from Hinner chamber by drawing 80 L of air through a filter and measuring limulus amebocyte lysate activity. The level of endotoxin in the aerosols include: air (0 µg/m3), endotoxin-reduced OVA (0 µg/m3), commercially available Sigma-Aldrich OVA (0.11 µg/m3), and contaminated OVA (0.18 µg/m3).
Generation of bone marrow chimeric mice
Bone marrow chimeric mice were created, as previously described (26). Briefly, 4 x 106 bone marrow cells from donor mice were transferred into lethally irradiated (10.5 Gy) recipient mice. Donor marrow engraftment was assessed by flow cytometric analysis of peripheral blood leukocytes 6 wk after the transplant, including: CD3+/CD4+ T cells, 83.499.4%; CD3+/CD8+ T cells, 77.899.9%; and B cells, 98.299.3%.
Flow cytometric analysis
To prepare parenchymal dendritic cells (DCs),4 lungs were perfused with HBSS/collagenase/DNase, minced, and digested at 37°C for 30 min. Lung tissue from five animals per group was pooled. Samples were then transferred to Ca-free HBSS/EDTA and layered over a 17% metrizamide solution and centrifuged at 700 x g. Cells at the interface were recovered, counted, blocked (CD16/CD32 (Fc
RIII/II), murine IgG, rat IgG), and stained with mAbs, including: CD11c, CD11b, I-A/I-E, Gr-1, CD3, CD19, CD40, CD80, CD86, B220, ICOS, IL-10, and glucocorticoid-induced TNFR. For airway DCs, 1 x 106 lavaged cells from lung lavage were resuspended in 100 µl of sterile endotoxin-free PBS with 0.1% sodium azide. Mediastinal lymph nodes were prepared similarly to parenchymal DCs. Cells were analyzed using FACSVantage SE (BD Biosciences) and counts were calculated automatically by FlowJo software (Tree Star).
Statistics
Data are expressed as mean ± SEM. Significant differences between groups were identified by ANOVA. Individual comparisons between groups were confirmed by Students t test, unless otherwise stated. A two-tailed p value of <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
To gain insight into mechanisms by which TLR4 affects allergic responses in the lung, we first compared pulmonary allergic responses in tlr4-deficient mice with those of genetically matched C57BL/6J mice in an acute model of allergen challenge (10). Sensitized and challenged tlr4-deficient mice had slightly more airway eosinophils than similarly sensitized and challenged C57BL/6J mice, but in most experiments this difference did not reach statistical significance (Fig. 1A). These data show that tlr4 does not markedly impact sensitization to OVA, or initial responses to the aerosolized protein.
|
In addition to eosinophil recruitment, Ig class switching from IgG to IgE and increases in airway hyperresponsiveness are other well-described hallmarks of allergic inflammation. We therefore measured serum levels of wild-type and tlr4-deficient mice after various periods of daily allergen challenges. Challenged tlr4-deficient mice had dramatic increases in serum IgE compared with wild-type mice, particularly after 1 wk of challenges (Fig. 1B). Moreover, ongoing challenged C3H/HeJ mice, which have a naturally occurring mutation in tlr4, also had significantly increased allergic responses compared with similarly challenged C3H/OuJ mice (data not shown). By contrast, responses of tlr2-deficient mice did not differ significantly from those of C57BL/6 mice (data not shown). In addition, we performed studies of airway physiology using noninvasive whole body plethysmography (Buxcos enhanced pause or Penh). No differences between the two strains were observed during the first 2 wk of exposures, although tlr4-deficient mice had increased hyperreactivity after 21 days of daily allergen challenge (Fig. 1C). Although airway hyperreactivity is generally associated with eosinophilic inflammation, this association is not always observed (27). Taken together, these findings demonstrate that tlr4 is specifically required to attenuate inflammatory responses to ongoing aeroallergen challenge, but not for airway hyperreactivity.
The tlr4-dependent regulation of allergic inflammation is dose dependent
Analysis of the commercially obtained OVA used to generate aerosols revealed that a 1% solution of this product contained
70 EU/mg endotoxin, a finding that is consistent with previous studies (16). We attempted to remove this contaminating endotoxin through the use of a purification kit, but were only able to reduce levels to
25 EU/mg. This preparation of OVA was used to generate aerosols for challenge of sensitized C57BL/6 and tlr4-deficient mice for 10 consecutive days. Challenged tlr4-deficient mice had significantly increased inflammation and serum IgE compared with challenged C57BL/6 mice (Fig. 2). This result demonstrates that in C57BL/6 mice, aerosols of OVA containing as little as 25 EU/mg are sufficient to attenuate inflammatory responses to ongoing allergen challenge.
|
Tolerance to inhaled OVA is tlr4 independent
Mice exposed to OVA aerosols before their sensitization become tolerant to that Ag and do not develop allergic responses when subsequently challenged (28). Our finding that tlr4 is required to attenuate ongoing allergic inflammation during ongoing allergen challenge suggested that this receptor might also be required to develop Ag-specific immune tolerance. To test this possibility, we exposed both wild-type and tlr4-deficient mice to an aerosol of 1% OVA before sensitizing and challenging these animals as before. This treatment caused both C57BL/6 and tlr4-deficient mice to become tolerant to OVA and unable to respond to subsequent sensitization and challenge (data not shown). To determine whether differences between these groups would become apparent at reduced concentrations of OVA, we used a 0.001% solution of this protein, and exposed animals for as little as 3 min. Again, tlr4-deficient and C57BL/6 mice became tolerant to OVA (Fig. 3). These data show that unlike the regulation of existing allergic responses, induction of tolerance by aerosols before sensitization is not dependent on tlr4 signaling. Therefore, the molecular mechanisms involved in conferring tolerance to inhaled allergens are most likely distinct, at least in part, from those that attenuate ongoing allergic responses.
|
Signaling from TLRs, including tlr4, leads to the production of Th1-associated cytokines such as IFN-
(29). It has been suggested that endotoxin-stimulated production of these Th1 cytokines might decrease Th2 cytokine production and thereby protect against the development of asthma. To test whether this mechanism might underlie the increased allergic responses in ongoing challenged tlr4-deficient mice, we measured airway levels of Th1 and Th2 cytokines. Compared with C57BL/6 mice, tlr4-deficient mice had increased level of the Th2 cytokine IL-5, particularly during the first week of challenge, as would be expected for mice having increased airway eosinophils and serum IgE (Fig. 4A). However, the level of the Th1 cytokine, IFN-
, was not correspondingly decreased between challenged C57BL/6 and tlr4-deficient mice (Fig. 4B). Moreover, serum levels of OVA-specific IgG2a, the Ig isotype associated with Th1 cytokine production (30), were dramatically increased in tlr4-deficient mice compared with similarly challenged C57BL/6 mice (Fig. 4C). Taken together, these data demonstrate that Th1 responses in tlr4-deficient mice are at least as robust as those of C57BL/6 mice. Therefore, a reduction in Th1 cytokine production does not account for the increased Th2-associated allergic inflammation seen in ongoing challenged tlr4-deficient mice.
|
The tlr4 is expressed on many cell types that might participate in attenuating allergic inflammation. In particular, both hemopoietic and nonhemopoietic cells have been shown previously to require tlr4 expression for inflammatory responses to endotoxin, depending on the route of endotoxin administration (26, 31, 32, 33, 34). To determine which of these cellular compartments requires tlr4 expression for attenuation of allergic inflammation, we generated bone marrow chimeric mice using C57BL/6 and tlr4-deficient mice. Because maximum differences between these two parental strains for eosinophilic inflammation and IgE levels were seen at 7 and 14 days, respectively, we challenged the limited number of chimeric animals at 10 days, midway between these two time points. Irradiated C57BL/6 and tlr4-deficient mice receiving C57BL/6 bone marrow developed relatively modest levels of eosinophilic inflammation and serum IgE after 10 consecutive days of OVA challenge (Fig. 5). By contrast, tlr4-deficient mice and C57BL/6 mice receiving tlr4-deficient bone marrow had high levels of eosinophilic inflammation and serum IgE, similar to those seen in nonirradiated, tlr4-deficient mice. These data demonstrate that a cell type derived from the bone marrow requires tlr4 expression to limit allergic responses to ongoing allergen challenge.
|
Within the hemopoietic compartment, there are several cell types whose immunoregulatory function might be affected by tlr4. Specifically, tlr4 expression has been reported in regulatory T cells (Treg) (35), macrophages (36), and DCs (37). We therefore used flow cytometry to determine the abundance of these cell types after various days of challenge. With regard to Treg cells, no differences were found in the number of CD25-expressing cells in thoracic lymph nodes of C57BL/6 and tlr4-deficient mice. In addition, the CD25-expressing cells of both genotypes expressed similar levels of the glucocorticoid-induced TNFR and IL-10, two molecules associated with the activities of Treg cells. Analysis of DCs in the lung and draining lymph nodes did not reveal differences in the cell surface levels of CD40, CD80, CD86, B220, ICOS, or MHC class II Ag (data not shown). However, after 1 wk of OVA exposures, the number of classical, CD11c+CD11b+ DCs expressing high levels of MHC class II was dramatically increased in the lung parenchyma of tlr4-deficient mice compared with similarly challenged C57BL/6 mice (Fig. 6). This difference coincides with the time at which tlr4-deficient mice begin to develop dramatic increases in pulmonary eosinophils and serum IgE compared with challenged C57BL/6 mice.
|
| Discussion |
|---|
|
|
|---|
In contrast to the protective effect of low levels of endotoxin, adding higher doses of endotoxin to OVA increased the magnitude of allergic responses in the lung. Taken together, these data demonstrate that the level of endotoxin associated with an allergen is critically important to the magnitude of ensuing allergic responses. The most likely explanation for these findings is that the proinflammatory effects of high levels of endotoxin override the attenuating affect of low levels of endotoxin. Interestingly, epidemiologic studies also suggest that low, but not high, levels of endotoxin can attenuate asthma. It is conceivable, therefore, that some epidemiologic studies have failed to reveal an overall association between endotoxin and asthma because of the opposing actions of low and high levels of endotoxin.
C3H/HeJ mice, which have a naturally occurring mutation in tlr4, are reported by Dabbagh et al. (38) to have diminished allergic responses following three intranasal challenges with OVA. In contrast, we found that in our model, C3H/HeJ mice had increased allergic inflammation compared with control C3H/OuJ mice following prolonged challenges with aerosolized allergen. No significant differences between C3H/HeJ and C3H/OuJ mice were seen after only a single aerosol challenge. These responses of tlr4-deficient C3H/HeJ mice in our model were therefore very similar to those of tlr4-deficient gene-targeted mice. Thus, differences in the procedures used to challenge the mice most likely account for the apparent discrepancy between our findings and those of Dabbagh et al. Although we have not compared responses of mice challenged with an intranasal application with those challenged multiple times with an OVA-based aerosol, it is noteworthy that intranasal administration of OVA containing low doses of endotoxin can sensitize naive mice (12), whereas exposure of naive mice to an aerosol of OVA can block responses in mice that are subsequently sensitized and challenged (28).
We cannot formally exclude the possibility that endogenous ligands of tlr4, or a contaminant in the OVA other than endotoxin, contribute to the diminished allergic responses seen in C57BL/6J mice compared with tlr4-deficient mice. We were unable to directly test this hypothesis because we were unable to completely remove endotoxin from our OVA. However, it is noteworthy that a different group of investigators using aseptic techniques to prepare OVA directly from chicken eggs found that inflammatory responses to LPS-free OVA are markedly increased compared with commercially obtained OVA (16). This would be the expected result if low levels of contaminating endotoxin account for negative regulation of allergic inflammation in wild-type mice. Whatever the relevant ligand(s), tlr4 signaling clearly leads to attenuation of ongoing inflammation in this model of ongoing allergen challenge. Therefore, this model can be used to determine whether low doses of endotoxin activate signaling pathways that are distinct from those pathways activated by high doses.
It has been suggested previously that the protective effect of pathogen infection seen in epidemiologic studies might result from TLR-stimulated production of Th1 cytokines, which would in turn inhibit Th2 cytokine production (39). Although tlr ligands can induce Th1 cytokine production in DCs, there is no direct evidence that these molecules diminish allergic responses (40, 41, 42). Moreover, several other studies suggest that an alternative mechanism might be responsible for the protective effect of pathogen exposure on asthma (41, 43). In our experiments, Th2 cytokine production in the lung was increased in tlr4-deficient mice compared with wild-type mice, but we did not see a corresponding decrease in Th1 cytokines. In fact, serum levels of the Th1-associated Ig isotype, IgG2a, were increased in tlr4-deficient mice in concert with IgE. While it remains possible that Th1 cytokine production in tissues other than the lung, such as the spleen, lymph nodes, or bone marrow, is different between wild-type and tlr4-deficient mice, our data support the notion that an increase in Th1 cytokines does not account for the lower levels of Th2 cytokines and other allergic responses seen in wild-type mice compared with tlr4-deficient mice.
The dramatic increase in the number of pulmonary DCs suggests that these cells might be related to increased allergic inflammation in tlr4-deficient mice. Although there is little evidence that Th2 cytokine production in DCs is a consequence of tlr4 signaling, DCs are nonetheless critical to allergic responses, not only for the sensitization phase, but also during the challenge phase (44). It is possible that low levels of endotoxin somehow attenuate the recruitment of DC precursors to the lung following allergen challenge, thereby limiting the magnitude of responses to that Ag. However, we cannot exclude the alternative possibility that the increase in pulmonary DCs seen in tlr4-deficient mice is secondary to the increased inflammation in these animals.
The reduced capacity of tlr4-deficient mice to regulate ongoing inflammation prompted us to study their ability to undergo Ag-specific tolerance when exposed to an aerosol of this protein before being sensitized. However, the abilities of wild-type and tlr4-deficient mice to undergo Ag-specific tolerance were indistinguishable, suggesting that the mechanisms leading to tolerance are different than those regulating ongoing inflammation.
Interestingly, another group of investigators found that naive mice exposed intranasally to endotoxin-containing OVA became sensitized to this allergen, in a tlr4-dependent manner (12). These findings demonstrate that the levels of endotoxin, or its activity, are critical for intranasal sensitization, as well as for regulating existing inflammation. However, these investigators found that tlr4 was not required for sensitization by i.p. injections of alum-complexed allergen. Although direct comparisons have not been made, we estimate that the low dose of endotoxin (0.1 µg) used in those experiments (12) contains
300 EU, which is roughly equivalent to the high dose used in our OVA challenges in which wild-type mice did not have attenuated inflammation compared with tlr4-deficient mice. Alternatively, there could be important differences in tolerance dependent on the mode of pre-exposure. It is possible that an aerosol exposure of Ag increased gut mucosal Ag exposure, leading to tolerance in lieu of sensitization to Ag. Additional experiments will be required to identify which experimental variation has the greatest impact on sensitization and generation of allergen-specific tolerance.
Taken together, the findings presented in this study demonstrate that tlr4 signaling regulates ongoing inflammatory responses to ongoing allergic challenge. This result is consistent with the epidemiologic finding that low doses of endotoxin, particularly in childhood, protect against developing asthma later in life. The tlr4-dependent attenuation of inflammation seen in C57BL/6 mice is not associated with an increase in Th1 cytokine production, an observation that is consistent with emerging models of allergic regulation in humans (45). Moreover, our finding that high doses of endotoxin overcome the anti-inflammatory effect is also consistent with the lack of inhibition or exacerbation of asthma seen with exposure to high levels of endotoxin in humans. The similarities between our experimental findings and previously described epidemiologic data suggest that this animal model will prove useful in further elucidating the underlying mechanism underlying the regulation of allergic inflammation. Such an improved understanding should facilitate the development of novel therapies to treat asthma by augmenting natural regulatory mechanisms.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by National Institute of Environmental Health Sciences Grants ES12717, ES7031, ES12496, ES11375, ES7498, and ES11961, National Heart, Lung, and Blood Institute Grant HL74538, and the Veterans Administration Medical Center. ![]()
2 Address correspondence and reprint requests to Dr. John W. Hollingsworth, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Box 3136, Durham, NC 27710. E-mail address: holli017{at}mc.duke.edu ![]()
3 Current address: National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709. ![]()
4 Abbreviations used in this paper: DC, dendritic cell; Treg, regulatory T cell. ![]()
Received for publication October 13, 2005. Accepted for publication February 18, 2006.
| References |
|---|
|
|
|---|
and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944-947.
B activation in response to endotoxin. Am. J. Respir. Cell Mol. Biol. 26: 572-578. This article has been cited by other articles:
![]() |
J A Frank, J-F Pittet, C Wray, and M A Matthay Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade Thorax, February 1, 2008; 63(2): 147 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. J. Schroder and M. Arditi IEIIS Meeting minireview: The role of innate immunity in the pathogenesis of asthma: evidence for the involvement of Toll-like receptor signaling Innate Immunity, October 1, 2007; 13(5): 305 - 312. [Abstract] [PDF] |
||||
![]() |
J. W. Hollingsworth, S. Maruoka, Z. Li, E. N. Potts, D. M. Brass, S. Garantziotis, A. Fong, W. M. Foster, and D. A. Schwartz Ambient Ozone Primes Pulmonary Innate Immunity in Mice J. Immunol., October 1, 2007; 179(7): 4367 - 4375. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Cook and K. Bottomly Innate Immune Control of Pulmonary Dendritic Cell Trafficking Proceedings of the ATS, July 1, 2007; 4(3): 234 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Van Hove, T. Maes, G. F. Joos, and K. G. Tournoy Prolonged Inhaled Allergen Exposure Can Induce Persistent Tolerance Am. J. Respir. Cell Mol. Biol., May 1, 2007; 36(5): 573 - 584. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Whitehead, T. Wang, L. M. DeGraff, J. W. Card, S. A. Lira, G. J. Graham, and D. N. Cook The Chemokine Receptor D6 Has Opposing Effects on Allergic Inflammation and Airway Reactivity Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 243 - 249. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |